Vera Therapeutics, Inc.
$41.61
▲
0.89%
2026-04-21 10:06:01
veratx.com
NGM: VERA
Explore Vera Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.02 B
Current Price
$41.61
52W High / Low
$56.05 / $18.76
Stock P/E
—
Book Value
$8.48
Dividend Yield
—
ROCE
-46.31%
ROE
-50.71%
Face Value
—
EPS
$-4.66
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
249
Beta
1.17
Debt / Equity
12.79
Current Ratio
13.63
Quick Ratio
13.64
Forward P/E
-14.8
Price / Sales
—
Enterprise Value
$2.58 B
EV / EBITDA
-8.18
EV / Revenue
—
Rating
Strong Buy
Target Price
$79
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Editas Medicine, Inc. | $3.57 | — | $349.4 M | — | -70.81% | -1.98% | $4.54 / $1.23 | $0.28 |
| 2. | Capricor Therapeutics, Inc. | $34.21 | — | $2.04 B | — | -33.78% | -46.56% | $40.37 / $4.3 | $5.33 |
| 3. | Oragenics, Inc. | $0.71 | — | $3.19 M | — | -113.05% | -2.44% | $9.6 / $0.5 | $1.94 |
| 4. | Armata Pharmaceuticals, Inc. | $12.5 | — | $421.28 M | — | -45.96% | 130.37% | $16.34 / $1.11 | $-6 |
| 5. | Silo Pharma, Inc. | $0.67 | — | $8.38 M | — | -61.55% | -74.57% | $1.19 / $0.22 | $0.47 |
| 6. | Relay Therapeutics, Inc. | $16.4 | — | $3 B | — | -50.82% | -41.12% | $17.32 / $2.53 | $3.26 |
| 7. | Annexon, Inc. | $6.43 | — | $1.05 B | — | -92.11% | -81.9% | $7.18 / $1.4 | $1.42 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -94.21 M | -83.93 M | -80.14 M | -57.19 M | -48.91 M | — |
| Net Profit | -91.1 M | -80.29 M | -76.53 M | -51.69 M | -43.42 M | — |
| EPS in Rs | -1.27 | -1.12 | -1.07 | -0.72 | -0.61 | -0.85 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -315.47 M | -167.17 M | -102.01 M | -90.9 M |
| Net Profit | -299.62 M | -152.15 M | -95.99 M | -89.06 M |
| EPS in Rs | -4.18 | -2.12 | -1.34 | -1.24 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 734.73 M | 655.68 M | 175.55 M | 131.44 M |
| Total Liabilities | 130.21 M | 78.53 M | 73.86 M | 54.53 M |
| Equity | 604.52 M | 577.15 M | 101.69 M | 76.91 M |
| Current Assets | 728.88 M | 651.22 M | 172.02 M | 125.7 M |
| Current Liabilities | 53.45 M | 25.37 M | 22.3 M | 25.6 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -241.1 M | -134.68 M | -92.18 M | -67.6 M |
| Investing CF | 194.29 M | -425.03 M | -39.43 M | -70.55 M |
| Financing CF | 308.9 M | 606.67 M | 133.54 M | 101.93 M |
| Free CF | -241.73 M | -135.65 M | -92.24 M | -67.66 M |
| Capex | -0.63 M | -0.97 M | -0.06 M | -0.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -58.5% | -7.79% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.